Glaxo, Genmab say disappointed with study of lymphoma treatment

(Reuters) – GlaxoSmithKline and Danish biotech company Genmab said disappointing results from a study on treating relapsed lymphoma with their ofatumumab drug meant it was unlikely they would seek its regulatory approval. A head-to-head phase III study of ofatumumab and another drug to fight the fast-growing blood cancer failed to meet the companies’ goals. Results showed no significant difference in progression free survival (PFS) between one treatment arm and the other, the companies said in a statement late on Monday. “Based on today’s results we are unlikely to move forward with a regulatory filing,” Jan Van De Winkel, Genmab chief executive said in the statement.